Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression
Lung Neoplasms
DRUG: Envafolimab|DRUG: Endostar
Objective Response Rate (ORR), The proportion of patients whose tumor volume has reduced to a predetermined value and can maintain the minimum time limit, up to 24 months|Number of participants with adverse events as a measure of safety and tolerability, From randomization until death (up to 24 months), up to 24 months
PFS, Progression-free survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months|DCR, Disease Control Rate, Each 42 days up to intolerance the toxicity or PD (up to 24 months)|OS, Overall survival, From randomization until death (up to 24 months)|DOR, Duration of response, Each 42 days up to intolerance the toxicity or PD (up to 24 months)
Endostar indication: ENDOSTAR + NP chemotherapy regimen is used to treat Stage III/IV NSCLC patients either untreated or pretreated. This indication is based on a completed multi-center Phase III clinical trial.

Envafolimab indication: Envolimab is the world's first subcutaneous injection of PD-L1 monoclonal antibody.Suitable for adult patients with advanced solid tumors with unresectable or metastatic microsatellite highly unstable (MSI-H) or mismatch repair gene defects (dMMR).